RO7566802

RO7566802 is an investigational biological drug being developed by Genentech for the treatment of solid tumors, including locally advanced, recurrent, or metastatic incurable solid tumor malignancies. It is currently in a first-in-human Phase I clinical trial to evaluate its safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and preliminary anti-tumor activity as both a single agent and in combination with atezolizumab (an approved immune checkpoint inhibitor). The precise mechanism of action for RO7566802 has not been publicly disclosed. The drug is classified as an antineoplastic agent and represents a new molecular entity[1][4][5][6].